US · MGX
Metagenomi, Inc. Common Stock
- Sector
- Healthcare · Biotechnology
- Headquarters
- Emeryville 94608
- Website
- metagenomi.co
Price · as of 2024-12-31
$1.39
Market cap 57.07M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $17.44 | +1,154.68% |
| Intrinsic Value(DCF) | $2.83 | +103.6% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | |||||
| 2021 | |||||
| 2022 | $0.00 | $0.00 | |||
| 2023 | $11.78 | $161.85 | $1,444,971.89 | $0.00 | $0.00 |
| 2024 | $2.07 | $17.44 | $33.56 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Metagenomi, Inc. Common Stock's (MGX) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $17.44
- Current price
- $1.39
- AI upside
- +1,154.68%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$2.83
+103.6% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| MGX | Metagenomi, Inc. Common S… | $1.39 | 57.07M | +1,155% | +104% | — | — | -0.99 | 0.33 | 1.48 | 1.50 | -6.69 | 0.33 | 100.00% | -170.00% | -149.26% | -34.69% | -676.50% | -22.64% | 0.19 | — | 6.91 | 6.69 | -0.22 | 1484.00% | 1684.00% | 1083.00% | -144.84% | -2.92 | -913.98% | 0.00% | 0.00% | 0.00% | 1.41 | 1.11 | -2.39 | -0.37 |
| ADVM | Adverum Biotechnologies, … | $4.36 | 96.26M | +263% | -58% | — | +9,149% | -0.69 | 1.28 | 90.60 | -0.44 | -0.30 | 1.28 | -265.30% | -15315.90% | -13092.70% | -169.83% | -313.49% | -74.21% | 1.30 | — | 5.73 | 5.49 | -0.24 | 22772.00% | -7222.00% | 124.00% | -102.48% | -4.04 | -190.05% | 0.00% | 0.00% | 0.00% | -0.37 | -0.61 | 56.62 | -9.89 |
| ALXO | ALX Oncology Holdings Inc… | $2.11 | 114.42M | — | — | — | — | -0.41 | 0.49 | — | 0.42 | — | 0.49 | 0.00% | — | — | -88.91% | -1054.84% | -69.10% | 0.15 | -82.40 | 7.26 | 6.95 | 0.00 | -3102.00% | — | -705.00% | -221.24% | -6.59 | -905.96% | 0.00% | 0.00% | 0.00% | 0.39 | 0.45 | — | -7.15 |
| ARTV | Artiva Biotherapeutics, I… | $5.82 | 142.85M | +335% | -18% | — | +3,479% | -2.00 | 0.70 | 520.26 | 0.62 | -0.59 | 0.70 | 100.00% | -26805.58% | -23303.98% | -530.93% | 65.16% | -41.55% | 0.08 | — | 15.39 | 15.15 | 0.40 | 33697.00% | -9925.00% | 984.00% | -42.63% | -4.49 | 53.92% | 0.00% | 0.00% | 3.20% | 0.60 | 0.73 | -161.31 | 1.72 |
| ATYR | aTyr Pharma, Inc. | $0.96 | 94.05M | +2,378% | +42% | — | +2,039% | -3.94 | 3.61 | 1074.42 | -2.92 | — | 3.61 | 100.00% | -28899.57% | -27243.83% | -79.69% | -723.88% | -58.88% | 0.19 | — | 5.48 | 4.93 | -0.03 | -851.00% | -3343.00% | 8481.00% | -27.40% | -4.62 | -737.41% | 0.00% | 0.00% | 0.00% | -2.85 | -2.80 | 824.03 | -3.56 |
| CNTB | Connect Biopharma Holding… | $2.47 | 138.08M | — | — | — | — | -3.00 | 0.51 | 1.80 | 2.14 | — | 0.51 | 100.00% | -86.24% | -60.03% | -16.18% | 242.61% | -13.76% | 0.00 | — | 11.46 | 11.20 | 3.58 | -7407.00% | — | -4948.00% | -51.91% | -2.79 | 263.24% | 0.00% | 0.00% | 0.00% | 2.08 | 1.91 | -1.79 | -1.11 |
| DTIL | Precision BioSciences, In… | $4.20 | 55.67M | +1,686% | -46% | +221% | +1,082% | 4.94 | 0.63 | 0.52 | -1.54 | — | 0.63 | 100.00% | -38.08% | 10.43% | 19.05% | 78.77% | 4.84% | 0.53 | -14.68 | 6.34 | 5.88 | -4.13 | -10652.00% | 4098.00% | -3206.00% | -165.83% | -3.90 | 176.73% | 0.00% | 0.00% | 0.00% | 0.80 | 0.36 | -0.30 | -4.11 |
| IFRX | InflaRx N.V. | $0.92 | 62.33M | +5,018% | -48% | — | — | -1.32 | 0.99 | 367.43 | -0.95 | — | 0.99 | -1900.76% | -31973.69% | -27784.96% | -56.18% | -78.66% | -46.95% | 0.01 | -2566.39 | 5.06 | 1.30 | 0.39 | 0.00% | 16279.00% | 2826.00% | -79.79% | -3.43 | -72.12% | 0.00% | 0.00% | 9.72% | -0.82 | -0.89 | 261.45 | -5.01 |
| KLRS | Kalaris Therapeutics Inc | $10.46 | 195.63M | — | — | — | — | -0.84 | 0.44 | — | 1.17 | — | 0.44 | 0.00% | — | — | -172.12% | 207.85% | -96.44% | 0.00 | — | 22.63 | 22.58 | 2.01 | -7213.00% | — | 37909.00% | -136.96% | -12.92 | 254.68% | 0.00% | 0.00% | 232.88% | 1.25 | 1.02 | — | -3.17 |
| QNCX | Quince Therapeutics, Inc. | $0.13 | 7M | — | — | — | — | -1.15 | 2.17 | — | -1.09 | -2.05 | -2.18 | 0.00% | — | — | -98.63% | -409.00% | -38.57% | 0.49 | — | 6.05 | 5.72 | -0.24 | 5595.00% | — | 7430.00% | -49.23% | -4.38 | -229.62% | 0.00% | 0.00% | 0.00% | -0.69 | -1.22 | — | -5.41 |
| STRO | Sutro Biopharma, Inc. | $20.47 | 174.27M | -71% | -71% | — | +6,969% | -0.51 | 2.58 | 1.86 | 0.99 | -0.76 | 2.58 | 88.37% | -384.34% | -366.62% | -234.19% | 108.03% | -53.02% | 0.52 | -7.67 | 2.60 | 2.47 | 0.93 | 6629.00% | -5964.00% | 6789.00% | -168.89% | -1.45 | 88.18% | 0.00% | 0.00% | 114.12% | 0.75 | 0.92 | -2.88 | -3.86 |
About Metagenomi, Inc. Common Stock
Metagenomi, Inc., a gene editing biotechnology company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.
- CEO
- Jian Irish
- Employees
- 202
- Beta
- 0.52
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($2.83 ÷ $1.39) − 1 = +103.6% (DCF, example).